Repurposing and re-positioning of old treatments for new indications: A focus on addictive disorders
Author(s)
MacDonald, Tim
Griffith University Author(s)
Year published
2018
Metadata
Show full item recordAbstract
Introduction and Aims
There are a plethora of biomedical treatments used in mainstream medical practice, for many well‐known diagnoses, some dating back for centuries. Despite the aging of most populations worldwide and the increasing global burdens of various diseases in recent decades, there has been a relative paucity in development of new treatments for neuropsychiatric conditions in particular. This is potentially due to big pharma retreating, microeconomic and macroeconomic constraints and the fastidious process of developing and then testing new molecules or treatments on a complex human brain. The benefits of ...
View more >Introduction and Aims There are a plethora of biomedical treatments used in mainstream medical practice, for many well‐known diagnoses, some dating back for centuries. Despite the aging of most populations worldwide and the increasing global burdens of various diseases in recent decades, there has been a relative paucity in development of new treatments for neuropsychiatric conditions in particular. This is potentially due to big pharma retreating, microeconomic and macroeconomic constraints and the fastidious process of developing and then testing new molecules or treatments on a complex human brain. The benefits of psychological, behavioural, mutual help and other treatments are generally well known and accepted; however, limitations for their use exist also. The author aims to summarise how some older medications are being used for new indications, in particular relating to addictive disorders. Design and Methods A précis of relevant literature and anecdotes is presented. The author presents an opinion on current trends in ‘off label’ medication use, and offer a glimpse into potential future applications. Results Numerous novel ways of repurposing treatments were discovered, including oxytocin for alcohol use disorder, lisdexamfetamine for stimulant use disorder and N‐acetyl cysteine for cannabis use disorder. A case series on subcutaneous flumazenil infusions for benzodiazepine use disorder was outlined. Discussion and Conclusions The modern era of medicine comes with it hope but also a degree of constriction which conflates to drive flexible and creative ways of treating refractory conditions. Amongst addictive disorders alone, there are a number of potentially beneficial repositioned treatments for which little or no research/consensus exists. The reasons driving a request (or behest), acceptance or reluctance to trial old approaches for novel reasons is often not congruent with evidence or based on biological plausibility. The scope for further research with many of these treatments is limited due to lack of financial incentives, but potentially less onerous if safety has been established in previous Phase I and II trials for other conditions. Disclosure of Interest Statement The author declares no conflict of interests related to this manuscript. TM has received honoraria, fees and/or provision of professional development resources from Servier, Otsuka/Lundbeck, Australian and New Zealand Mental Health Association, and Healthe Care. He works in the private sector and receives income for clinical services provided.
View less >
View more >Introduction and Aims There are a plethora of biomedical treatments used in mainstream medical practice, for many well‐known diagnoses, some dating back for centuries. Despite the aging of most populations worldwide and the increasing global burdens of various diseases in recent decades, there has been a relative paucity in development of new treatments for neuropsychiatric conditions in particular. This is potentially due to big pharma retreating, microeconomic and macroeconomic constraints and the fastidious process of developing and then testing new molecules or treatments on a complex human brain. The benefits of psychological, behavioural, mutual help and other treatments are generally well known and accepted; however, limitations for their use exist also. The author aims to summarise how some older medications are being used for new indications, in particular relating to addictive disorders. Design and Methods A précis of relevant literature and anecdotes is presented. The author presents an opinion on current trends in ‘off label’ medication use, and offer a glimpse into potential future applications. Results Numerous novel ways of repurposing treatments were discovered, including oxytocin for alcohol use disorder, lisdexamfetamine for stimulant use disorder and N‐acetyl cysteine for cannabis use disorder. A case series on subcutaneous flumazenil infusions for benzodiazepine use disorder was outlined. Discussion and Conclusions The modern era of medicine comes with it hope but also a degree of constriction which conflates to drive flexible and creative ways of treating refractory conditions. Amongst addictive disorders alone, there are a number of potentially beneficial repositioned treatments for which little or no research/consensus exists. The reasons driving a request (or behest), acceptance or reluctance to trial old approaches for novel reasons is often not congruent with evidence or based on biological plausibility. The scope for further research with many of these treatments is limited due to lack of financial incentives, but potentially less onerous if safety has been established in previous Phase I and II trials for other conditions. Disclosure of Interest Statement The author declares no conflict of interests related to this manuscript. TM has received honoraria, fees and/or provision of professional development resources from Servier, Otsuka/Lundbeck, Australian and New Zealand Mental Health Association, and Healthe Care. He works in the private sector and receives income for clinical services provided.
View less >
Conference Title
Drug and Alcohol Review
Volume
37
Issue
S3
Publisher URI
Subject
Medical and Health Sciences
Studies in Human Society
Psychology and Cognitive Sciences
Science & Technology
Life Sciences & Biomedicine
Substance Abuse